The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Taking to platforms including Reddit and Telegram for guidance, buyers import small quantities, often described as research ...

In the same way weight varies from person to person, so do the best weight loss strategies. While some people succeed with ...

Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain FDA approval by 2026.

A separate Prime analysis, however, of year-over-year claims data for Wegovy and Zepbound only found an improvement in ...